NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction

NewAmsterdam Pharma Co N.V.

Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.
Observed 21% reduction in MACE (exploratory endpoint) at one year; hazard ratio 0.79 (95% CI 0.54-1.15).
Obicetrapib well-tolerated: TEAEs 59.8% vs placebo 60.9%; discontinuation 11.1% vs 12.4%.
NewAmsterdam plans to present additional BROADWAY data at upcoming medical meetings and discuss filings with regulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.